NCT06953986View on ClinicalTrials.gov

A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks

NARecruitingINTERVENTIONAL

Enrollment

414

Participants

Timeline

Start Date

June 7, 2025

Primary Completion Date

November 20, 2026

Study Completion Date

December 12, 2027

Conditions

GERD

Interventions

DRUG

Vonoprazan

Vonaprazon is potassium competitive acid blockers

DRUG

Esomeprazole 40mg

esomeprazole is a proton pump inhibitor as it prevents excess of gastric acid secretion in the stomach

Trial Locations (1)

500082

RECRUITING

Asian Institute of Gastroenterology /Aig Hospitals, Hyderabad

All Listed Sponsors

lead

Asian Institute of Gastroenterology, India

OTHER

NCT06953986 - A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks | Biotech Hunter | Biotech Hunter